{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:25:45Z","timestamp":1781843145922,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12325-026-03506-6","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:18:23Z","timestamp":1773130703000},"page":"1827-1844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Content Validation of the Flares Diary: A Qualitative Analysis of the Flares Experience Within the Fibrodysplasia Ossificans Progressiva (FOP) Population"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03188666","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jessica","family":"Baldasaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hartford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Dahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Pignolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle E.","family":"Altman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"4","key":"3506_CR1","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bone.2012.07.002","volume":"51","author":"A Morales-Piga","year":"2012","unstructured":"Morales-Piga A, Bachiller-Corral J, Trujillo-Tiebas MJ, et al. Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects. Bone. 2012;51(4):748\u201355. https:\/\/doi.org\/10.1016\/j.bone.2012.07.002.","journal-title":"Bone"},{"issue":"1","key":"3506_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0674-5","volume":"12","author":"G Baujat","year":"2017","unstructured":"Baujat G, Choquet R, Bou\u00e9e S, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: a estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017;12(1):123. https:\/\/doi.org\/10.1186\/s13023-017-0674-5.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3506_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.29245\/2572-9411\/2020\/2.1196","volume":"5","author":"M Liljesthr\u00f6m","year":"2020","unstructured":"Liljesthr\u00f6m M, Pignolo RJ, Kaplan FS. Epidemiology of the global fibrodysplasia ossificans progressiva (FOP) community. J Rare Dis Res Treat. 2020;5(2):31\u20136. https:\/\/doi.org\/10.29245\/2572-9411\/2020\/2.1196.","journal-title":"J Rare Dis Res Treat"},{"issue":"1","key":"3506_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01983-2","volume":"16","author":"RJ Pignolo","year":"2021","unstructured":"Pignolo RJ, Hsiao EC, Baujat G, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J Rare Dis. 2021;16(1):350. https:\/\/doi.org\/10.1186\/s13023-021-01983-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3506_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1068-7","volume":"14","author":"RJ Pignolo","year":"2019","unstructured":"Pignolo RJ, Baujat G, Brown MA, et al. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis. 2019;14(1):98. https:\/\/doi.org\/10.1186\/s13023-019-1068-7.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3506_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.berh.2007.11.007","volume":"22","author":"FS Kaplan","year":"2008","unstructured":"Kaplan FS, Le Merrer M, Glaser DL, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008;22(1):191\u2013205. https:\/\/doi.org\/10.1016\/j.berh.2007.11.007.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"3506_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11832-015-0704-6","volume":"9","author":"F Ortiz-Agapito","year":"2015","unstructured":"Ortiz-Agapito F, Colmenares-Bonilla D. Quality of life of patients with fibrodysplasia ossificans progressiva. J Child Orthop. 2015;9(6):489\u201393. https:\/\/doi.org\/10.1007\/s11832-015-0704-6.","journal-title":"J Child Orthop"},{"issue":"12","key":"3506_CR8","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/jbmr.3235","volume":"32","author":"J Upadhyay","year":"2017","unstructured":"Upadhyay J, Xie L, Huang L, et al. The expansion of heterotopic bone in fibrodysplasia ossificans progressiva is activin A-dependent. J Bone Miner Res. 2017;32(12):2489\u201399. https:\/\/doi.org\/10.1002\/jbmr.3235.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"3506_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/wdev.9","volume":"1","author":"EM Shore","year":"2012","unstructured":"Shore EM. Fibrodysplasia ossificans progressiva: a human genetic disorder of extraskeletal bone formation, or\u2013how does one tissue become another? WIREs Dev Biol. 2012;1(1):153\u201365. https:\/\/doi.org\/10.1002\/wdev.9.","journal-title":"WIREs Dev Biol"},{"issue":"2","key":"3506_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2106\/00004623-199302000-00008","volume":"75","author":"RB Cohen","year":"1993","unstructured":"Cohen RB, Hahn GV, Tabas JA, et al. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am. 1993;75(2):215\u20139. https:\/\/doi.org\/10.2106\/00004623-199302000-00008.","journal-title":"J Bone Joint Surg Am"},{"issue":"3","key":"3506_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jbmr.2728","volume":"31","author":"RJ Pignolo","year":"2016","unstructured":"Pignolo RJ, Bedford-Gay C, Liljesthrom M, et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Miner Res. 2016;31(3):650\u20136. https:\/\/doi.org\/10.1002\/jbmr.2728.","journal-title":"J Bone Miner Res"},{"key":"3506_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/ORR.S337491","volume":"14","author":"BJ Smilde","year":"2022","unstructured":"Smilde BJ, Botman E, de Ruiter RD, et al. Monitoring and management of fibrodysplasia ossificans progressiva: current perspectives. Orthop Res Rev. 2022;14:113\u201320. https:\/\/doi.org\/10.2147\/ORR.S337491.","journal-title":"Orthop Res Rev"},{"issue":"8","key":"3506_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10181","volume":"3","author":"K Peng","year":"2019","unstructured":"Peng K, Cheung K, Lee A, et al. Longitudinal evaluation of pain, flare-up, and emotional health in fibrodysplasia ossificans progressiva: analyses of the International FOP Registry. JBMR Plus. 2019;3(8):e10181. https:\/\/doi.org\/10.1002\/jbm4.10181.","journal-title":"JBMR Plus"},{"issue":"3","key":"3506_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.7324\/japs.2023.130303","volume":"13","author":"S Mahapatra","year":"2023","unstructured":"Mahapatra S, Muragundi PM, Choughule S, Piruka A. A literature review of HRQoL and prevalence of fibrodysplasia ossificans progressiva. J Appl Pharm Sci. 2023;13(3):53\u20139. https:\/\/doi.org\/10.7324\/japs.2023.130303.","journal-title":"J Appl Pharm Sci"},{"issue":"5","key":"3506_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38(5):525\u20137. https:\/\/doi.org\/10.1038\/ng1783.","journal-title":"Nat Genet"},{"issue":"303","key":"3506_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac4358","volume":"7","author":"SJ Hatsell","year":"2015","unstructured":"Hatsell SJ, Idone V, Wolken DMA, et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med. 2015;7(303):303ra137. https:\/\/doi.org\/10.1126\/scitranslmed.aac4358.","journal-title":"Sci Transl Med"},{"key":"3506_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.bone.2017.06.011","volume":"109","author":"DM Alessi Wolken","year":"2018","unstructured":"Alessi Wolken DM, Idone V, Hatsell SJ, Yu PB, Economides AN. The obligatory role of activin A in the formation of heterotopic bone in fibrodysplasia ossificans progressiva. Bone. 2018;109:210\u20137. https:\/\/doi.org\/10.1016\/j.bone.2017.06.011.","journal-title":"Bone"},{"issue":"50","key":"3506_CR18","doi-asserted-by":"publisher","first-page":"15438","DOI":"10.1073\/pnas.1510540112","volume":"112","author":"K Hino","year":"2015","unstructured":"Hino K, Ikeya M, Horigome K, et al. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci U S A. 2015;112(50):15438\u201343. https:\/\/doi.org\/10.1073\/pnas.1510540112.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"3506_CR19","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A. 2014;111(14):5147\u201352. https:\/\/doi.org\/10.1073\/pnas.1323896111.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"3506_CR20","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111(14):5153\u20138. https:\/\/doi.org\/10.1073\/pnas.1324022111.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"3506_CR21","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1038\/s41591-023-02561-8","volume":"29","author":"M Di Rocco","year":"2023","unstructured":"Di Rocco M, Forleo-Neto E, Pignolo RJ, et al. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med. 2023;29(10):2615\u201324. https:\/\/doi.org\/10.1038\/s41591-023-02561-8.","journal-title":"Nat Med"},{"issue":"1","key":"3506_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00219-4","volume":"4","author":"S Cruz Rivera","year":"2020","unstructured":"Cruz Rivera S, McMullan C, Jones L, et al. The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders. J Patient Rep Outcomes. 2020;4(1):51. https:\/\/doi.org\/10.1186\/s41687-020-00219-4.","journal-title":"J Patient Rep Outcomes"},{"key":"3506_CR23","unstructured":"Food and Drug Administration. Guidance for industry\u2014patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/media\/77832\/download. Accessed Sep 7 2023."},{"issue":"8","key":"3506_CR24","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DP Patrick","year":"2011","unstructured":"Patrick DP, Burke LB, Gwaltney CJ, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 1\u2013eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377. https:\/\/doi.org\/10.1016\/j.jval.2011.06.014.","journal-title":"Value Health"},{"key":"3506_CR25","doi-asserted-by":"publisher","DOI":"10.4324\/9780203413081","volume-title":"Analyzing qualitative data","author":"A Bryman","year":"2002","unstructured":"Bryman A, Burgess RG. Analyzing qualitative data. New Yor: Routledge; 2002."},{"key":"3506_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1098214005283748","volume":"27","author":"RD Thomas","year":"2006","unstructured":"Thomas RD. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27:237\u201346. https:\/\/doi.org\/10.1177\/1098214005283748.","journal-title":"Am J Eval"},{"key":"3506_CR27","volume-title":"Research methods in health: Investigating health and health services","author":"A Bowling","year":"2009","unstructured":"Bowling A. Research methods in health: Investigating health and health services. 3rd ed. Maidenhead: Open University Press; 2009.","edition":"3"},{"issue":"8","key":"3506_CR28","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1524-4733.2009.00603.x","volume":"12","author":"M Rothman","year":"2009","unstructured":"Rothman M, Burke L, Erickson P, et al. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report. Value Health. 2009;12(8):1075\u201383. https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00603.x.","journal-title":"Value Health"},{"issue":"12","key":"3506_CR29","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.gim.2022.08.013","volume":"24","author":"JR Pignolo","year":"2022","unstructured":"Pignolo JR, Baujat G, Brown AM, et al. The natural history of fibrodysplasia ossificans progressiva: a prospective, global 36-month study. Genet Med. 2022;24(12):2422\u201333. https:\/\/doi.org\/10.1016\/j.gim.2022.08.013.","journal-title":"Genet Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03506-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03506-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03506-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:14:01Z","timestamp":1775726041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03506-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3506"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03506-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jessica Baldasaro and Danielle E. Altman are employees of Modus Outcomes. Robert J. Sanchez and Christopher Hartford are employees of and stockholders in Regeneron Pharmaceuticals, Inc. Kathryn M. Dahir is a principal investigator on the Regeneron Pharmaceuticals, Inc. LUMINA-1 trial. The project described was supported by CTSA award No. UL1 TR002243 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors\/sponsor and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. Richard Keen is a principal investigator of clinical trials sponsored by Clementia\/Ipsen and Regeneron Pharmaceuticals, Inc; and a non-paid member of the International Clinical Council on FOP and the IFOPA FOP registry medical advisory board. Thomas Funck-Brentano is a principal investigator for trials sponsored by Regeneron Pharmaceuticals, Inc., Ipsen, and Incyte. Robert J. Pignolo is a principal investigator of the Regeneron Pharmaceuticals, Inc. LUMINA-1 and Clementia\/Ipsen MOVE trials; and a founding member and past president of the International Clinical Council (ICC) on FOP. At the time of the study, Michelle Davis was a non-paid member of the Rare Bone Disease Alliance Steering Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval for this study was provided by the Western Institutional Review Board-Copernicus Group (WCG\n                      \u00ae\n                      IRB) for research in the United States and Canada. For LUMINA-1 trial participants who participated at trial sites in the European Union, regulatory oversight was granted under the aegis of the clinical trial. In the UK, institutional review board oversight was not required as confirmed by the Health Research Authority decision tool for ethics review requirements;\n                      \n                      . All participants provided written informed consent to be included in the study and for the results of the study to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}